ArticleJournal of cardiovascular translational research2026
Suppression of Calpain Attenuates Coxsackievirus B3-Induced Myocarditis by Regulating RIPK1/RIPK3/MLKL Pathway.
Article in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Viral myocarditis caused by CVB3 inflicts substantial myocardial damage and predisposes to heart failure. Although necroptosis contributes to disease progression, the mechanisms governing this death pathway during CVB3 infection remain unclear. We found that calpain and its inhibitor Cast were dynamically expressed during CVB3 infection, correlating with cardiac damage, inflammation, and fibrosis. Further investigation revealed that CVB3 dynamically induced cardiomyocyte necroptosis by activating the RIPK1/RIPK3/MLKL pathway, which was prominently activated in the early acute phase but potentially attenuated in later stages. Immunofluorescence analysis supported the translocation of p-MLKL from the nucleus to the plasma membrane during disease progression. Importantly, both in vivo and in vitro experiments supported that calpain inhibition ALLN attenuated VMC via the RIPK1/RIPK3/MLKL pathway, and improved cardiac function post-CVB3 infection. The calpain activator PMMA exacerbated this process. Our findings reveal that calpain inhibition attenuated VMC by modulating the RIPK1/RIPK3/MLKL pathway, uncovering a novel regulatory mechanism in VMC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.